Stifel raised the firm’s price target on Tandem Diabetes to $55 from $45 and keeps a Buy rating on the shares. The firm’s continued monthly Mobi diligence, “again” found multiple positive and confirmatory data points, including still-increasing “interest”, patient/physician satisfaction, and sustained adoption expectations, the analyst tells investors. The survey work increases the firm’s conviction that Mobi will drive positive 2024 new prescription growth for Tandem, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem mobile app ‘recall’ a ‘non-event,’ says Stifel
- FDA announces Tandem Diabetes recall of t:connect mobile app
- Tandem Diabetes price target raised to $55 from $39 at Barclays
- Tandem Diabetes price target raised to $50 from $35 at Piper Sandler
- Tandem Diabetes price target raised to $50 from $45 at Wells Fargo